drugset / Trial / NCT02601365

Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia

NCT02601365

NaSingle-groupOpen-labelTreatment

Summary

This study will investigate the safety and efficacy of the administration of inhaled GM-CSF to patients with respiratory virus-associated pneumonia.

Timeline

Start
2019-03
Primary completion
2019-05
Completion
2019-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject sargramostim Protein / enzyme biologic 0.04 ug/kg Other
Subject sargramostim Protein / enzyme biologic 0.2 ug/kg Other
Subject sargramostim Protein / enzyme biologic 1 ug/kg Other